- Thaden JT, Fowler VG, Sexton DJ, Anderson DJ. Increasing incidence of extended spectrum β-lactamase producing Escherichia coli in community hospitals throughout the southeastern United States. Infect Control Hosp Epidemiol. 2016;37:49–54.
- Castanheira M, Farrell SE, Krause KM, Jones RN, Sader HS. Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine US census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase group. Antimicrob Agents Chemother. 2014;58:833–838.
- Endimiani A, Luzzaro F, Brigante G, et al. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 2005;49:2598–2605. doi: 10.1128/AAC.49.7.2598-2605.2005.
- Hoban DJ, Lascols C, Nicolle LE, et al. Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009–2010. Diagn Microbiol Infect Dis. 2012;74:62–67. doi: 10.1016/j.diagmicrobio.2012.05.024.
- Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657–686. doi: 10.1128/CMR.18.4.657-686.2005.
- Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012;67:2793–2803. doi: 10.1093/jac/dks301.
- Shiber S, Yahav D, Avni T, Leibovici L, Paul M. β-Lactam/β-lactamase inhibitors versus carbapenems for the treatment of sepsis: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2015;70:41–47. doi: 10.1093/jac/dku351.
- Ng TM, Khong WX, Harris PNA, et al. Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae. PLoS One. 2016;11:e0153696. doi: 10.1371/journal.pone.0153696.
- Tamma PD, Han JH, Rock C, et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia. Clin Infect Dis. 2015;60:1319–1325.
- Altman DG, Bland JM. How to randomise. BMJ. 1999;319:703–704.
- Ghafourian S, Sadeghifard N, Soheili S, Sekawi Z. Extended spectrum beta-lactamases: definition, classification and epidemiology. Curr Issues Mol Biol. 2015;17:11–22.
- Ben-Ami R, Rodriguez-Bano J, Arslan H, et al. A multinational survey of risk factors for infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis. 2009;49:682–690. doi: 10.1086/604713.
- Lee CH, Chu FY, Hsieh CC, et al. A simple scoring algorithm predicting extended-spectrum β-lactamase producers in adults with community-onset monomicrobial Enterobacteriaceae bacteremia. Medicine (Baltimore). 2017;96:e6648. doi: 10.1097/MD.0000000000006648.
- Rodriguez-Bano J, Picon E, Gijon P, et al. Community-onset bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: risk facts and prognosis. Clin Infect Dis. 2010;50:40–48.
- Harris PNA, Tambyah PA, Lye DC, et al. Effect of piperacillin-tazobactam vs meropenem on 30 day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA. 2018;320:984–994. doi: 10.1001/jama.2018.12163.
- Chen LF, Freeman JT, Nicholson B, et al. Widespread dissemination of CTX-M-15 genotype extended-spectrum-β-lactamase-producing Enterobacteriaceae among patients presenting to community hospitals in the southeastern United States. Antimicrob Agents Chemother. 2014;58:1200–1202. doi: 10.1128/AAC.01099-13.
- Cantón R, Coque TM. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol. 2006;9:466–475. doi: 10.1016/j.mib.2006.08.011.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 32, 2019 - Issue 2
Original Research
Outcomes analysis in patients with extended-spectrum beta-lactamase bacteremia empirically treated with piperacillin/tazobactam versus carbapenems
Reeba JohnDepartment of Pharmacy, Baylor University Medical Center, Dallas, Texas; 
http://orcid.org/0000-0002-4731-7588
, PharmD http://orcid.org/0000-0002-4731-7588, Peter ColleyDepartment of Pharmacy, Baylor University Medical Center, Dallas, Texas; Correspondence[email protected]
http://orcid.org/0000-0003-1415-8602
, PharmD, BCPS AQ-ID http://orcid.org/0000-0003-1415-8602, Hoa L. NguyenDepartment of Quantitative Sciences, Baylor Scott and White Health, Dallas, Texas; http://orcid.org/0000-0002-4998-8510
, MD, MS, PhD http://orcid.org/0000-0002-4998-8510 & Mezgebe BerheDivision of Infectious Diseases, Department of Internal Medicine, Baylor University Medical Center, Dallas, Texashttp://orcid.org/0000-0002-7287-567X
, MD, MPH http://orcid.org/0000-0002-7287-567X